For muscle invasive bladder cancer, after neoadjuvant chemotherapy with cis/gem and surgery with residual tumor and lymph node involvement, would you consider adjuvant avelumab as an extrapolation base on the JAVELIN 100 results?
https://meetinglibrary.asco.org/record/186872/abstract
How do you weigh the negative results from IMvigor 010 of adjuvant atezolizumab vs the results of JAVELIN 100 showing benefit of switch maintenance avelumab?
Answer from: Medical Oncologist at Community Practice
I would not use adjuvant avelumab following radical cystectomy finding residual high risk disease after neoadjuvant chemotherapy. Biologically, this group has disease resistant to neoadjuvant chemotherapy, and is not akin to those with stable or responding disease following platinum therapy included...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Adjuvant (post-op) setting with NED is very different than switch maintenance strategy after induction chemotherapy in the 1L setting. IMvigor010 did not meet the primary endpoint of DFS but we are awaiting (Checkmate 274, Ambassador, and Proof 302) adjuvant trials. I would not use IO in the adjuvan...